Zarontin (ethosuximide) NDC 0071-0237

NDC codes

FDA NDC Directory

Product NDC (as listed)0071-0237Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00071-0237Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0071-0237-24	00071023724	100 CAPSULE in 1 BOTTLE (0071-0237-24)Marketed from Sep 22, 2000

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zarontin
Generic name (nonproprietary): ethosuximide
Active ingredients: Ethosuximide — 250 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Parke-Davis Div of Pfizer Inc
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 012380
Marketing start: Sep 22, 2000
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 0071-0237_b5966080-3265-4027-b1f6-67af24097f18SPL ID b5966080-3265-4027-b1f6-67af24097f18SPL set ID 0e008f33-70a1-4bc6-b3a0-d45214418ab6RxCUI 197682, 201737UNII 5SEH9X1D1DUPC 0300710237247
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400071023724 followed by a unit qualifier and the quantity

Package 00071-0237-24. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 25, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Zarontin is indicated for the control of absence (petit mal) epilepsy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)